Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Ilford, United Kingdom Clinical Trials

A listing of Ilford, United Kingdom clinical trials actively recruiting patients volunteers.

Found (59) clinical trials

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 (olutasidenib) as a single agent or in combination with azacitidine or cytarabine. The Phase 1 stage of the study is split into 2 distinct parts: a dose escalation part, which will utilize an open-label design of …

Phase

9.41 miles

Learn More »

A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

This study is a phase I/II, open-label study in patients with relapsed indolent non-Hodgkin lymphoma. Part A of the study included a phase I dose escalation to define the maximum tolerated / recommended dose for expansion of (177Lu)-lilotomab (Betalutin), and a phase IIa part to evaluate safety and preliminary efficacy. …

Phase

9.41 miles

Learn More »

A Study of PRN1008 in Adult Patients With Immune Thrombocytopenic Purpura (ITP)

This is an adaptive, open-label, dose-finding study of PRN1008 in up to 40 patients with ITP who are refractory or relapsed with no available and approved therapeutic options, with a platelet count <30,000/L on two counts no sooner than 7 days apart in the 15 days before treatment begins. The …

Phase

9.41 miles

Learn More »

Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma

This is a two part, phase I, single centre dose escalation and dose expansion study to establish the safety, tolerability and pharmacokinetics of pembrolizumab in combination with different dose levels of fixed dose rate gemcitabine in patients with newly diagnosed metastatic or inoperable leiomyosarcoma and undifferentiated pleomorphic sarcoma (UPS), for …

Phase

9.41 miles

Learn More »

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

This is an open labeled, multi-center, phase I/II, cohort study involving a single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID in up to 10 patients with X-linked SCID (SCID-X1) at Boston Children's Hospital and UCLA Mattel Children's Hospital. Patients will receive transduced cells after …

Phase

9.41 miles

Learn More »

A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent -Thalassemia

This is a single-arm, open-label, multi-site, single-dose Phase 1/2 study in subjects with transfusion-dependent -thalassemia (TDT). The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 Modified CD34+ Human Hematopoietic Stem and Progenitor Cells (hHSPCs) using CTX001.

Phase

9.41 miles

Learn More »

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab

RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly destroy tumors and to generate an anti-tumor immune response. This is a Phase 1/2, open label, multicenter, dose escalation and expansion, first-in-human (FIH) clinical study to evaluate the safety and tolerability, biodistribution, shedding, and preliminary …

Phase

9.41 miles

Learn More »

G1T38 a CDK 4/6 Inhibitor in Combination With Fulvestrant in Hormone Receptor-Positive HER2-Negative Locally Advanced or Metastatic Breast Cancer

This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in combination with fulvestrant in patients with hormone receptor-positive, HER2-negative metastatic breast cancer. The study is an open-label design, consists of 2 parts: dose-finding portion (Part 1), and expansion portion (Part 2). Both parts …

Phase

9.42 miles

Learn More »

Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2

This study will evaluate the role of increasing radiotherapy dose and addition of nelfinavir to chemoradiotherapy (CRT) in patients with inoperable pancreatic cancer that has not spread beyond the pancreas. Currently in the United Kingdom (UK), either chemotherapy alone or chemotherapy followed by CRT can be used in the management …

Phase

9.42 miles

Learn More »

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Unresectable solid tumour is a tumour that cannot be removed completely through surgery, radiation therapy, drug treatment or any combination of them. AGI-134 (alpha-Gal) is a synthetic molecule that by intratumoural injection trigger a systemic anti-tumour response. This study will evaluate the safety, tolerability and efficacy of AGI-134 given alone …

Phase

9.43 miles

Learn More »